Home › NDC Lookup › RxCUI directory › RxCUI 198317

Triazolam 0.125 MG Oral Tablet — RxCUI 198317

RxNorm drug concept · Semantic clinical drug
RxCUI 198317 Semantic clinical drug · SCD ● Current RxNorm concept 6 FDA products 15 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI198317
Official nameTriazolam 0.125 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped6
Package NDCs mapped15
Reported Medicaid activity (SDUD)30,021 prescriptions · 44 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Triazolam: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Triazolam is used for short-term relief of insomnia — trouble falling or staying asleep. It's generally prescribed for just 7 to 10 days. It's not meant to be a long-term sleep sol...
  • Take one tablet by mouth right before you get into bed — only when you have a full night ahead of you and don't need to be up and alert within several hours. Don't take it with alc...
  • Yes, this is a real concern. Your body can become physically dependent on triazolam, especially if you take it regularly or at higher doses. If you stop suddenly, you can have with...
  • The most common ones are drowsiness, dizziness, light-headedness, and headache — basically extensions of how the medicine makes you sleepy. Some people also notice coordination pro...
📖 Read our full Triazolam guide →

🕸️ Concept Web — How Triazolam 0.125 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Triazolam 0.125 MG Oral Tablet RxCUI 198317

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Triazolam 10767
  2. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Triazolam Oral Tablet 374197
    • Triazolam Oral Product 1158236
    • Triazolam Pill 1158237
    • Oral Tablet 317541
    • Oral Product 1151131
    • Pill 1151133
  3. Clinical & branded drugs 1

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Triazolam 0.125 MG 316855

Showing up to 8 concepts per family — 8 of 8 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Triazolam 0.125 MG SCDC · 316855
  • Triazolam Oral Tablet SCDF · 374197
  • Triazolam Oral Product SCDG · 1158236
  • Triazolam Pill SCDG · 1158237

📦 FDA Products & Package NDCs

6 products · 15 package NDCs
15 package NDCs map to RxCUI 198317 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
50742-0645-01 100 TABLET in 1 BOTTLE, PLASTIC (50742-645-01) Triazolam Ingenus Pharmaceuticals, LLC 2020-10-20
50742-0646-01 100 TABLET in 1 BOTTLE, PLASTIC (50742-646-01) Triazolam Ingenus Pharmaceuticals, LLC 2020-10-20
50742-0646-05 500 TABLET in 1 BOTTLE, PLASTIC (50742-646-05) Triazolam Ingenus Pharmaceuticals, LLC 2020-10-20
70710-1289-01 100 TABLET in 1 BOTTLE (70710-1289-1) Triazolam Zydus Pharmaceuticals USA Inc. 2022-12-30
70710-1289-05 500 TABLET in 1 BOTTLE (70710-1289-5) Triazolam Zydus Pharmaceuticals USA Inc. 2022-12-30
70710-1289-08 10 TABLET in 1 BOTTLE (70710-1289-8) Triazolam Zydus Pharmaceuticals USA Inc. 2022-12-30
70710-1521-01 100 TABLET in 1 BOTTLE (70710-1521-1) Triazolam Zydus Pharmaceuticals USA Inc. 2022-12-30
70710-1521-05 500 TABLET in 1 BOTTLE (70710-1521-5) Triazolam Zydus Pharmaceuticals USA Inc. 2022-12-30
70710-1521-08 10 TABLET in 1 BOTTLE (70710-1521-8) Triazolam Zydus Pharmaceuticals USA Inc. 2022-12-30
70771-1162-01 100 TABLET in 1 BOTTLE (70771-1162-1) Triazolam Zydus Lifesciences Limited 2022-12-30
70771-1162-05 500 TABLET in 1 BOTTLE (70771-1162-5) Triazolam Zydus Lifesciences Limited 2022-12-30
70771-1162-08 10 TABLET in 1 BOTTLE (70771-1162-8) Triazolam Zydus Lifesciences Limited 2022-12-30
70771-1576-01 100 TABLET in 1 BOTTLE (70771-1576-1) Triazolam Zydus Lifesciences Limited 2022-12-30
70771-1576-05 500 TABLET in 1 BOTTLE (70771-1576-5) Triazolam Zydus Lifesciences Limited 2022-12-30
70771-1576-08 10 TABLET in 1 BOTTLE (70771-1576-8) Triazolam Zydus Lifesciences Limited 2022-12-30
Observed labelers: Zydus Lifesciences Limited (6) · Zydus Pharmaceuticals USA Inc. (6) · Ingenus Pharmaceuticals, LLC (3) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.